Weekly Sepsis Research Analysis
This week’s sepsis literature highlights actionable advances across pathophysiology, diagnostics, and infection prevention. A mechanistic preclinical study identifies endothelial CLEC5A as a causal driver of vascular leakage and lung injury, opening a new therapeutic target. Large human transcriptomic work demonstrates that the causative pathogen explains substantial host-response variance and provides an externally validated 8‑gene streptococcal classifier to inform pathogen-directed care. Comp
Summary
This week’s sepsis literature highlights actionable advances across pathophysiology, diagnostics, and infection prevention. A mechanistic preclinical study identifies endothelial CLEC5A as a causal driver of vascular leakage and lung injury, opening a new therapeutic target. Large human transcriptomic work demonstrates that the causative pathogen explains substantial host-response variance and provides an externally validated 8‑gene streptococcal classifier to inform pathogen-directed care. Complementing these biologic insights, a quasi-experimental ICU genomics-informed study questions universal decolonisation practices by linking chlorhexidine pressure to MRSE selection, guiding infection-prevention policies.
Selected Articles
1. Endothelial CLEC5A drives barrier dysfunction and vascular leakage responsible for lung injury in bacterial pneumonia and sepsis.
In murine CLP and LPS models, endothelial CLEC5A was shown to causally drive inflammatory vascular leakage, cytokine storm amplification, and mortality. Endothelial-specific CLEC5A knockdown improved survival and reduced lung injury, with scRNA-seq revealing endothelial transcriptomic changes in CLEC5A-deficient lungs.
Impact: Identifies a specific endothelial pattern-recognition receptor (CLEC5A) as a tractable molecular driver of barrier failure in sepsis, providing a concrete target for therapies to prevent vascular leakage and lung injury.
Clinical Implications: Therapeutic strategies that inhibit endothelial CLEC5A (e.g., blocking antibodies or antagonists) could reduce vascular leakage and lung injury in bacterial pneumonia and sepsis; validation in human tissues and translational models is a priority.
Key Findings
- Clec5a−/− mice had decreased mortality in CLP and LPS models versus wild-type.
- Endothelial-specific CLEC5A knockdown improved survival; endothelial reexpression abrogated benefit, supporting endothelial causality.
- Protection correlated with attenuated cytokine surge and reduced vascular leakage; scRNA-seq revealed endothelial heterogeneity changes after CLEC5A deletion.
2. Pathogen-specific host response in critically ill patients with blood stream infections: a nested case-control study.
In a multi-cohort transcriptomic and biomarker study (n=341), the causative pathogen explained 41.8% of host blood transcriptomic variance in bloodstream infection. Streptococcal BSIs elicited the strongest innate/adaptive signatures and an externally validated 8‑gene streptococcal classifier was developed; E. coli and S. aureus showed distinct cytokine and endothelial activation profiles respectively.
Impact: Advances precision diagnostics by linking pathogen identity to validated host-response signatures and delivering a practical small-gene classifier for streptococcal BSI, enabling earlier pathogen-class inference and tailored therapy.
Clinical Implications: Transcriptome-based classifiers and targeted biomarker panels could be developed into rapid assays to inform initial antimicrobial choice and adjunctive interventions (e.g., endothelial stabilisers for S. aureus BSI) before culture results.
Key Findings
- Causative pathogen accounted for 41.8% of blood transcriptomic variance in BSI patients.
- Streptococcal BSI produced the strongest innate/adaptive immune activation; an 8‑gene classifier for streptococci validated externally.
- E. coli BSI associated with strong cytokine/systemic inflammation signals; S. aureus with endothelial activation signatures.
3. Universal versus targeted chlorhexidine and mupirocin decolonisation and clinical and molecular epidemiology of Staphylococcus epidermidis bloodstream infections in patients in intensive care in Scotland, UK: a controlled time-series and longitudinal genotypic study.
A before-after-control-impact time-series study across two Scottish ICUs (2009–2022) found de-escalation from universal to targeted skin/nasal decolonisation did not increase overall BSI but significantly reduced MRSE bloodstream infections and the proportion of multidrug-resistant SE genotypes. MRSE-BSI incidence correlated with chlorhexidine use, and WGS/MLST showed fewer MDR sequence types after de‑escalation.
Impact: Challenges the assumption that universal decolonisation is uniformly beneficial by linking chlorhexidine pressure to selection of MRSE and showing benefits of targeted strategies in low‑MRSA ICUs—directly relevant to infection prevention policy.
Clinical Implications: ICUs with low MRSA prevalence should consider targeted rather than universal decolonisation and implement resistome/genotypic surveillance when using biocidal agents like chlorhexidine to avoid selecting invasive MRSE lineages.
Key Findings
- De-escalation from universal to targeted decolonisation did not increase overall BSI incidence but reduced MRSE-BSI from 10.4 to 4.3 per 1000 OBDs at the intervention ICU.
- Probability that SE-BSI were MRSE fell from ~89.2% to ~56.7% after de-escalation.
- MRSE-BSI incidence density was positively associated with chlorhexidine use; genotyping/WGS showed fewer multidrug-resistant sequence types post-de-escalation.